Meeting
2023 ASCO Annual Meeting
Cell-free DNA in plasma and ascites as a biomarker of bevacizumab response: A translational sub-study of the REZOLVE (ANZGOG-1101) clinical trial.
Authors
Bonnita Werner
UNSW, Sydney, Australia
Bonnita Werner , Katrin Marie Sjoquist , David Espinoza , Sonia Yip , Garry Chang , Michelle M. Cummins , Linda R. Mileshkin , Sumitra Ananda , Catherine M. Shannon , Michael Friedlander , Kristina Warton , Caroline Ford
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Gynecologic Cancer
Track
Gynecologic Cancer
Sub Track
Ovarian Cancer
Citation
J Clin Oncol 41, 2023 (suppl 16; abstr 5561)
DOI
10.1200/JCO.2023.41.16_suppl.5561
Abstract #
5561
Poster Bd #
256
Abstract Disclosures
Similar Posters
Poster
2024 ASCO Annual Meeting
Evaluation of prognostic and predictive values of bespoke circulating tumor DNA assay in patients with advanced epithelial ovarian cancer.
First Author: Hao Wen
Poster
2019 ASCO Annual Meeting
Multimodality liquid biopsy for early monitoring and outcome prediction in first-line metastatic HER2-negative breast cancer: Final results of the prospective cohort from the French Breast Cancer InterGroup Unicancer (UCBG)— COMET study.
First Author: Jean-Yves Pierga
Poster
2017 ASCO Annual Meeting
Circulating free DNA and circulating tumor cells as new serum biomarkers in advanced ovarian cancer.
First Author: Jeronimo Martinez garcia
Poster
2017 ASCO Annual Meeting
Baseline cell-free DNA (cfDNA) and metabolic tumor volume (MTV) independently predict outcome in metastatic chemorefractory colorectal cancer (mCRC).
First Author: Erwin Woff